Latest Content in Huntington's Disease
CHDI 2019 poster: Resting state electroencephalography (EEG) biomarkers in Huntington’s disease (HD): Feasibility, reliability and relation to HD pathology
This study assessed the potential of resting-state-EEG-derived measures as biomarkers for HD using baseline resting-state EEG acquired in 46 participants of a Phase I/IIa study in early manifest HD (Stage 1).
CHDI 2019 poster: Positron emission tomography (PET) biodistribution study and radiation dosimetry of a radiolabeled HTT-ASO after intrathecal (IT) administration in rats
This study conducted in rats assessed the feasibility of PET imaging to track the distribution and uptake of intrathecally administered radiolabelled RG6042, an antisense oligonucleotide drug candidate for HD
HSG 2018 poster: Digital, high-frequency, long-term monitoring of motor and non-motor symptoms in Huntington’s disease (HD)
An open-label extension study is underway that includes the use of smartphones and other wrist-worn wearable technology to assess the reliability of these digital technologies in effectively measuring HD symptoms in daily life using at-home tests and continuous movement tracking.
HSG 2018 poster: Validity, reliability, ability to detect change and meaningful within-patient change of the cUHDRS
The composite Unified Huntington’s Disease Ratings Scale (cUHDRS) is a combined score of measures of motor function (TMS), cognition (SDMT and SWR) and overall functional capacity (TFC). The cUHDRS was developed to assess multi-domain clinical progression in HD. This poster includes estimates of clinically meaningful change of the cUHDRS and its individual measures.
HSG 2018 poster: Enrichment strategy in early-to-moderate manifest Huntington’s disease (HD) based on CAG-Age Product (CAP) ≥400 threshold
This poster highlights the value of applying a CAP threshold as an inclusion criterion in a hypothetical clinical trial of early-to-moderate manifest HD in order to identify a more homogeneous pattern of clinical progression on key clincial endpoints.
HSG 2018 poster: Partial lowering of total huntingtin levels to treat adults with Huntington’s disease (HD): potential benefits and theoretical risks from human studies and animal models
This poster presents a review of published clinical and preclinical studies on the effect of lowering wtHTT.
HSG 2018 Plenary: A Global Development Program Testing RG6042, an Antisense Oligonucleotide, for the Treatment of Early Manifest Huntington’s Disease (extract)
Extract of the plenary session by Roche lead scientist Scott Schobel at HSG 2018 outlining the design of the Global Development Program for RG6042 in HD.
HSG 2018 poster: Design of a prospective, longitudinal, natural history study in Huntington’s disease (HD)
This poster outlines the design of a study aiming to provide information on the relationship between levels of mHTT and a wide range of assessments that measure HD-related symptoms and their impact on daily function over a 15-month period.